TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

BACKGROUND: The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear. METHODS: We enrolled 84 adult patients with AML or MDS in a single-institution trial of decitabine to identify somatic muta...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Main Authors: Welch, John S., Petti, Allegra A., Miller, Christopher A., Fronick, Catrina C., O'Laughlin, Michelle, Fulton, Robert S., Wilson, Richard K., Baty, Jack D., Duncavage, Eric J., Tandon, Bevan, Lee, Yi-Shan, Wartman, Lukas D., Uy, Geoffrey L., Ghobadi, Armin, Tomasson, Michael H., Pusic, Iskra, Romee, Rizwan, Fehniger, Todd A., Stockerl-Goldstein, Keith E., Vij, Ravi, Oh, Stephen T., Abboud, Camille N., Cashen, Amanda F., Schroeder, Mark A., Jacoby, Meagan A., Heath, Sharon E., Luber, Kierstin, Janke, Megan R., Hantel, Andrew, Khan, Niloufer, Sukhanova, Madina J., Knoebel, Randall W., Stock, Wendy, Graubert, Timothy A., Walter, Matthew J., Westervelt, Peter, Link, Daniel C., DiPersio, John F., Ley, Timothy J.
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5217532/
https://ncbi.nlm.nih.gov/pubmed/27959731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1605949
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares